Science & health
FDA’s proposed Tavneos withdrawal exposes unresolved questions about drug evidence and oversight
The FDA is seeking to withdraw Tavneos, a treatment for a rare autoimmune disease, after alleging that its pivotal trial involved undisclosed, protocol-violating reassessment of patients and citing serious liver injuries, including deaths. The drug’s owner, Amgen, disputes that the conduct amounted to data manipulation and says other evidence supports continued use. The case now moves through a formal hearing process, leaving patients and physicians uncertain while raising broader questions about post-approval oversight and incentives for small biotechnology companies.
Editorial summary · Publisher article
What matters
- The FDA says ChemoCentryx employees reassessed selected patients after unblinding trial data, potentially changing the apparent efficacy result.
- The New England Journal of Medicine retracted the trial paper, while Tavneos has been removed from the European Union market and is expected to leave the UK market.
- Amgen says an independent reassessment found patients on Tavneos did no worse on one-year remission and points to real-world evidence of reduced steroid use.
- FDA withdrawal requires notice and an opportunity for a public hearing; Amgen could challenge a final decision in court.
Why the trial was difficult to interpret
The original trial gave the comparison group less rituximab than some clinicians considered standard practice, and the FDA says later reassessment of selected patients was not disclosed. That left experts divided over whether the reported benefit was reliable.
The unresolved evidence dispute
Amgen argues that the underlying clinical data were not altered and that the reassessment corrected errors. Critics say the pivotal trial is compromised and that several supporting studies remain unpublished or have not undergone peer review.
Context & caveats
- The FDA has proposed withdrawal, but the US approval remains subject to a formal process and the dispute is not settled.
- The article reports allegations and competing interpretations; it does not independently establish that the drug is ineffective.
Why this made the edition
Detailed reporting documents the FDA’s proposed withdrawal of Tavneos, alleged trial-data manipulation, safety concerns, competing evidence and the legal process still ahead.
Source material